LU92915I2 - Ivermectine pour son usage dans le traitement de la rosacée - Google Patents

Ivermectine pour son usage dans le traitement de la rosacée Download PDF

Info

Publication number: LU92915I2
Authority: LU; Luxembourg
Prior art keywords: rosaceae; ivermectin; treatment
Prior art date: 2003-04-24

Application number

LU92915C

Other languages

English (en)

Original Assignee

Galderma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-24

Filing date

2015-12-17

Publication date

2016-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92915(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-24 Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr

2015-12-17 Application filed by Galderma Sa filed Critical Galderma Sa

2016-02-17 Publication of LU92915I2 publication Critical patent/LU92915I2/fr

Links

AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 title 1
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 title 1
235000004789 Rosa xanthina Nutrition 0.000 title 1
241000220222 Rosaceae Species 0.000 title 1
229960002418 ivermectin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

LU92915C 2003-04-24 2015-12-17 Ivermectine pour son usage dans le traitement de la rosacée LU92915I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0305048A FR2854074B1 (fr)	2003-04-24	2003-04-24	Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P	2003-05-09	2003-05-09
PCT/EP2004/004950 WO2004093886A1 (fr)	2003-04-24	2004-04-22	Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques

Publications (1)

Publication Number	Publication Date
LU92915I2 true LU92915I2 (fr)	2016-02-17

Family

ID=33312271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92915C LU92915I2 (fr)	2003-04-24	2015-12-17	Ivermectine pour son usage dans le traitement de la rosacée

Country Status (16)

Country	Link
US (6)	US7550440B2 (fr)
EP (1)	EP1620113B1 (fr)
JP (2)	JP5711867B2 (fr)
KR (1)	KR101187231B1 (fr)
AU (1)	AU2004231323C1 (fr)
BR (1)	BRPI0410503B8 (fr)
CA (1)	CA2522579C (fr)
CY (2)	CY1111797T1 (fr)
FR (1)	FR15C0069I2 (fr)
HU (1)	HUS1500048I1 (fr)
LT (1)	LTC1620113I2 (fr)
LU (1)	LU92915I2 (fr)
MX (1)	MXPA05011208A (fr)
PL (2)	PL378932A1 (fr)
RU (1)	RU2350333C3 (fr)
WO (1)	WO2004093886A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2854074B1 (fr)	2003-04-24	2007-11-23	Galderma Res & Dev	Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (fr) *	2003-04-24	2004-11-04	Galderma S.A.	Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
US7648711B2 (en) *	2003-05-25	2010-01-19	Yuwan Wang	Dimethicone-containing sustained release injection formulation
DE602005020912D1 (de)	2004-03-18	2010-06-10	Galderma Sa	Ivermectin enthaltende creme
FR2867684B1 (fr) *	2004-03-18	2006-05-05	Galderma Sa	Gel creme contenant de l'ivermectine
FR2883181B1 (fr)	2005-03-17	2007-05-18	Galderma Sa	Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) *	2005-06-10	2007-11-23	Galderma Sa	Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886851B1 (fr) *	2005-06-10	2007-10-05	Galderma Sa	Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886850B1 (fr) *	2005-06-10	2007-10-05	Galderma Sa	Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr)	2005-12-20	2008-02-29	Galderma Sa	Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) *	2006-04-19	2011-02-18	Galderma Sa	Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) *	2006-09-28	2012-09-21	Galderma Sa	Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) *	2006-10-12	2012-09-21	Galderma Sa	Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr)	2006-10-12	2012-09-21	Galderma Sa	Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
EP2091325B1 (fr)	2006-10-12	2014-08-06	Topaz Pharmaceuticals Inc.	Formulation shampooing-après-shampooing comprenant un avermectine pour l'élimination et la prophylaxie contre les souches de poux sensibles et résistantes aux traitements
US8901163B2 (en) *	2007-01-03	2014-12-02	Galderma S.A.	Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) *	2007-11-23	2009-05-28	Neopharmacie Gmbh	Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
JP5694944B2 (ja) *	2008-10-29	2015-04-01	トパズファーマシューティカルズインコーポレイティド	エマルション系局所治療用製剤の保存方式
JP2012513387A (ja) *	2008-12-23	2012-06-14	ガルデルマ・ソシエテ・アノニム	感水性の活性成分を含む、局所用医薬組成物
ES2658897T3 (es)	2011-08-24	2018-03-12	Novan, Inc.	Macromoléculas de liberación de óxido nítrico ajustables que tienen múltiples estructuras donantes de óxido nítrico
US8642665B2 (en)	2011-12-16	2014-02-04	Conopco, Inc.	Environmentally friendly, low whitening compositions
JP5717034B2 (ja) *	2012-08-27	2015-05-13	丸和バイオケミカル株式会社	マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh)	2012-10-19	2016-06-01	厦门大学	一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) *	2013-03-29	2016-01-01	Galderma Sa	Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9782425B2 (en)	2013-07-08	2017-10-10	Galderma S.A.	Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) *	2013-07-08	2016-01-12	Galderma S. A.	Treatment of inflammatory lesions of rosacea with ivermectin
US11813284B2 (en)	2013-08-08	2023-11-14	Novan, Inc.	Topical compositions and methods of using the same
WO2015079016A1 (fr)	2013-11-29	2015-06-04	Galderma Sa	Compose de la famille des avermectines ou de la famille des milbemycines pour le traitement et/ou la prevention de dermatite atopique
CN104706584A (zh) *	2013-12-16	2015-06-17	天津迈迪瑞康生物医药科技有限公司	一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en)	2014-07-11	2019-06-18	Novan, Inc.	Topical antiviral compositions and methods of using the same
WO2016022066A1 (fr) *	2014-08-04	2016-02-11	Jerry Tan Eye Surgery Pte Ltd	Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
FR3026010B1 (fr) *	2014-09-18	2016-11-04	Galderma Sa	Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096797A1 (fr)	2014-12-15	2016-06-23	Galderma Sa	Composé de la famille des avermectines associé à un autre composé actif en vue du traitement et/ou de la prévention des dermatoses inflammatoires
WO2016096795A1 (fr) *	2014-12-15	2016-06-23	Galderma Sa	Composé de la famille des avermectines utilisable en vue du traitement et/ou de la prévention de dermatoses inflammatoires
EP3362045B1 (fr)	2015-10-13	2019-10-09	Galderma S.A.	Procédé de préparation d'une composition ayant une concentration élevée des avermectins
WO2017064205A1 (fr)	2015-10-13	2017-04-20	Galderma Sa	Procédé de préparation d'une émulsion stable comprenant une ou de plusieurs avermectines
EP3493795A1 (fr)	2016-08-04	2019-06-12	Nestlé Skin Health SA	Formule de traitement ou de prévention de la couperose.
US11160780B2 (en) *	2016-09-30	2021-11-02	Aurobindo Pharma Ltd.	Pharmaceutical composition of ivermectin and process for preparation thereof
US11234959B2 (en)	2016-11-03	2022-02-01	Galderma Holding SA	Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326614A1 (fr)	2016-11-24	2018-05-30	Nestlé Skin Health SA	Composition comprenant des composés d'avermectine sans solvants et agents pro-pénétrants de composés d'avermectine
EP3326609A1 (fr)	2016-11-24	2018-05-30	Nestlé Skin Health SA	Composition comprenant des composés d'avermectine sans agents de gélification
EP3326608A1 (fr)	2016-11-24	2018-05-30	Nestlé Skin Health SA	Composition comprenant des composés d'avermectine sans matières grasses solides
KR20260035292A (ko) *	2017-06-12	2026-03-12	레이크우드 아메덱스, 인크.	비스포스포신 겔 제제 및 이의 용도
AU2018385766B2 (en)	2017-12-15	2022-12-01	Tarsus Pharmaceuticals, Inc.	Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019241498A1 (fr)	2018-06-15	2019-12-19	W. R. Grace & Co.-Conn	Agent antimousse actif, son procédé de fabrication et formulation de démoussage
SG11202102783QA (en) *	2018-09-28	2021-04-29	Galderma Res & Dev	Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en)	2019-04-04	2025-12-23	Tarsus Pharmaceuticals, Inc.	Method of eradicating ticks that attach to humans using lotilaner formulations
WO2020210784A1 (fr)	2019-04-12	2020-10-15	Ecolab Usa Inc.	Nettoyant antimicrobien multi-usages et procédés de fabrication et d'utilisation de celui-ci
US12161752B2 (en)	2019-08-20	2024-12-10	Vishwanath Padmanabhan	Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
CN115379824A (zh) *	2019-08-21	2022-11-22	生物制药股份有限公司	用于局部递送活性剂的溶剂递送系统
KR20220052474A (ko)	2020-10-21	2022-04-28	순천향대학교 산학협력단	주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
KR102480430B1 (ko)	2020-10-21	2022-12-21	순천향대학교 산학협력단	주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
US11291679B1 (en) *	2021-03-22	2022-04-05	Mountain Valley Md Inc.	Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr)	2021-03-23	2022-09-28	Substipharm	Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5332577A (en)	1988-12-27	1994-07-26	Dermamed	Transdermal administration to humans and animals
GB9422306D0 (en) *	1994-11-04	1994-12-21	Sandoz Ltd	Organic compounds
US5952371A (en) *	1996-10-16	1999-09-14	Merck & Co., Inc.	Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) *	1997-09-22	1999-09-27	Мосин Владимир Александрович	Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) *	1998-09-17	1999-09-14	Mcdaniel; William Robert	Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) *	1998-11-24	2001-10-30	Picker International, Inc.	Source-assisted attenuation correction for emission computed tomography
IL144561A0 (en) *	1999-01-25	2002-05-23	Optime Therapeutics Inc	Liposome compositions and methods for treating pests utilizing the same
US6133310A (en) *	1999-08-26	2000-10-17	Parks; L. Dean	Method of treatment of rosacea
US6720001B2 (en) *	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) *	2000-06-29	2002-06-04	L. Dean Parks	Method of treating acne vulgaris using avermectin compound
US6319945B1 (en)	2000-06-29	2001-11-20	L. Dean Parks	Method of treatment of seborrheic dermatitis
US6399651B1 (en)	2000-06-29	2002-06-04	L. Dean Parks	Method of treating dermatoses using avermectin compound
US20030064940A1 (en) *	2001-10-02	2003-04-03	Parks L. Dean	Kit for treating acne vulgaris using avermectin compound
DE10063946A1 (de) *	2000-12-20	2002-07-04	Basf Ag	Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (fr) *	2002-02-08	2010-10-27	Merck Sharp & Dohme	Composition topique d'ivermectine
CN1649578A (zh) *	2002-03-04	2005-08-03	戴弗根斯公司	杀线虫的脂肪酸和脂肪酸酯相关化合物
WO2004093886A1 (fr) *	2003-04-24	2004-11-04	Galderma S.A.	Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
DE602005020912D1 (de)	2004-03-18	2010-06-10	Galderma Sa	Ivermectin enthaltende creme
FR2867684B1 (fr)	2004-03-18	2006-05-05	Galderma Sa	Gel creme contenant de l'ivermectine

2004
- 2004-04-22 WO PCT/EP2004/004950 patent/WO2004093886A1/fr not_active Ceased
- 2004-04-22 PL PL378932A patent/PL378932A1/pl not_active Application Discontinuation
- 2004-04-22 PL PL04728811T patent/PL1620113T3/pl unknown
- 2004-04-22 RU RU2005136438A patent/RU2350333C3/ru active Protection Beyond IP Right Term
- 2004-04-22 JP JP2006505405A patent/JP5711867B2/ja not_active Expired - Lifetime
- 2004-04-22 KR KR1020057019402A patent/KR101187231B1/ko not_active Expired - Lifetime
- 2004-04-22 CA CA2522579A patent/CA2522579C/fr not_active Expired - Fee Related
- 2004-04-22 BR BRPI0410503A patent/BRPI0410503B8/pt not_active IP Right Cessation
- 2004-04-22 EP EP04728811A patent/EP1620113B1/fr not_active Expired - Lifetime
- 2004-04-22 MX MXPA05011208A patent/MXPA05011208A/es active IP Right Grant
- 2004-04-22 AU AU2004231323A patent/AU2004231323C1/en active Active
2005
- 2005-10-24 US US11/255,910 patent/US7550440B2/en not_active Expired - Lifetime
2009
- 2009-05-19 US US12/468,287 patent/US8080530B2/en not_active Expired - Lifetime
- 2009-06-12 US US12/483,604 patent/US8093219B2/en not_active Expired - Lifetime
2011
- 2011-09-07 CY CY20111100856T patent/CY1111797T1/el unknown
- 2011-12-02 US US13/310,633 patent/US8415311B2/en not_active Expired - Fee Related
2012
- 2012-03-22 JP JP2012065724A patent/JP5538461B2/ja not_active Expired - Lifetime
- 2012-06-21 US US13/529,971 patent/US8470788B2/en not_active Expired - Fee Related
2013
- 2013-03-27 US US13/851,816 patent/US8598129B2/en not_active Expired - Fee Related
2015
- 2015-09-22 HU HUS1500048C patent/HUS1500048I1/hu unknown
- 2015-09-24 LT LTPA2015033C patent/LTC1620113I2/lt unknown
- 2015-10-14 FR FR15C0069C patent/FR15C0069I2/fr active Active
- 2015-12-17 LU LU92915C patent/LU92915I2/fr unknown
2016
- 2016-09-09 CY CY2016031C patent/CY2016031I2/el unknown

Also Published As

Publication number	Publication date
EP1620113A1 (fr)	2006-02-01
CA2522579A1 (fr)	2004-11-04
US7550440B2 (en)	2009-06-23
AU2004231323C1 (en)	2016-11-03
BRPI0410503B1 (pt)	2018-07-10
RU2350333C3 (ru)	2018-08-24
RU2005136438A (ru)	2006-05-27
JP2006524212A (ja)	2006-10-26
CY1111797T1 (el)	2015-10-07
PL1620113T3 (pl)	2011-10-31
JP5711867B2 (ja)	2015-05-07
FR15C0069I1 (fr)	2015-12-04
JP5538461B2 (ja)	2014-07-02
US8093219B2 (en)	2012-01-10
WO2004093886A1 (fr)	2004-11-04
US20130209381A1 (en)	2013-08-15
US20090227668A1 (en)	2009-09-10
CA2522579C (fr)	2012-08-28
PL378932A1 (pl)	2006-06-12
FR15C0069I2 (fr)	2016-04-22
CY2016031I1 (el)	2017-03-15
US20060100165A1 (en)	2006-05-11
AU2004231323A1 (en)	2004-11-04
US20120258062A1 (en)	2012-10-11
US8415311B2 (en)	2013-04-09
RU2350333C2 (ru)	2009-03-27
LTC1620113I2 (lt)	2018-02-26
HUS1500048I1 (hu)	2017-10-30
BRPI0410503A (pt)	2006-06-20
US20120077766A1 (en)	2012-03-29
US8598129B2 (en)	2013-12-03
KR101187231B1 (ko)	2012-10-02
EP1620113B1 (fr)	2011-07-13
AU2004231323B2 (en)	2009-12-10
US8470788B2 (en)	2013-06-25
BRPI0410503B8 (pt)	2021-05-25
JP2012126738A (ja)	2012-07-05
US20090252797A1 (en)	2009-10-08
KR20060004667A (ko)	2006-01-12
CY2016031I2 (el)	2017-03-15
MXPA05011208A (es)	2005-12-14
US8080530B2 (en)	2011-12-20

Publication	Publication Date	Title
LU92915I2 (fr)	2016-02-17	Ivermectine pour son usage dans le traitement de la rosacée
EP1711191A4 (fr)	2008-12-17	Chlorite dans le traitement de maladie neurodegenerative
EP1636359A4 (fr)	2006-09-13	Methodes de traitement de la douleur
EP1606301A4 (fr)	2006-06-14	Agents therapeutiques aptameres utiles dans la pharmacotherapie oculaire
EP1755584A4 (fr)	2007-10-31	Traitement de la myopie
DK1506781T3 (da)	2005-06-13	Vaginalplejesammensætning
EP1765288A4 (fr)	2009-05-13	Methodes de traitement d'infections endobronchiques
CY2016035I1 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
CY2015025I1 (el)	2016-04-13	Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
EP2185202A4 (fr)	2013-11-06	Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique
EP1696877A4 (fr)	2010-06-09	Methodes pour traiter la douleur
EP1613308A4 (fr)	2008-02-20	Procedes de traitement du cancer
DE60328797D1 (de)	2009-09-24	Blutbehandlungsgerät
EP1810034A4 (fr)	2008-06-25	Marqueurs predictifs utilises dans le traitement du cancer
EP1628530A4 (fr)	2007-08-29	Procedes et compositions pour la prevention et le traitement de la sepsie
EP1830876A4 (fr)	2009-06-03	Traitement de metastases cutanees
EP1727530A4 (fr)	2009-10-21	Formulations topiques pour le traitement d'etats dermatologiques
EP1660009A4 (fr)	2010-02-17	Methodes de traitement de l'endometriose
DE602004017075D1 (de)	2008-11-27	Optometrisches Instrument
EP1776136A4 (fr)	2009-12-09	Traitement d'etats pathologiques impliquant la demyelinisation
EP1485109A4 (fr)	2009-07-29	Traitement vasculaire
EP1838714A4 (fr)	2009-09-02	Procedes de traitement de la douleur
FR2887450B1 (fr)	2007-08-24	Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
DE60223576D1 (de)	2007-12-27	Hautbehandlungszusammensetzung
ATE399523T1 (de)	2008-07-15	Haarbehandlungszusammensetzung